The phase 3 double-blind, multicentric randomized-controlled ADAPT study assessed the efficacy and safety of efgartigimod as add-on therapy in 167 patients with gMG on a stable dose of at least one IS treatment, including 129 (77%) AChR-MG patients, 6 (4%) MuSK-MG patients and 32 double (AChR/MuSK-) negative patients (92) (Table 2). The gene discussed is MUSK; the disease is myasthenia gravis.